Post a Free Blog

Submit A Press Release

At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessSeaport Research Issues Rare Sell Rating on Nvidia Amid AI “Fully Priced”...

Seaport Research Issues Rare Sell Rating on Nvidia Amid AI “Fully Priced” Concerns

Add to Favorite
Added to Favorite


Seaport’s Bearish Case: Valuation, Deployment Hurdles, and Customer Risks
Seaport Research Partners stunned the Street Wednesday by assigning Nvidia (NASDAQ:NVDA) a Sell rating with a $100 price target, arguing that AI-driven upside is already baked into the stock.

“Nvidia is one of the leading beneficiaries of the current AI spending boom, but its prospects are well understood and largely priced into the stock,” Seaport wrote in its note.

Key concerns highlighted by Seaport include:

Fully Reflected AI Gains: With next-gen Blackwell chips sold out for 2025, Seaport warns there’s limited upside remaining.

Deployment Complexity: Significant cooling, configuration, and orchestration challenges could slow customer rollouts and inflate costs.

Return on Investment Uncertainty: Enterprise clients still “search for use cases and ways to generate returns” on existing AI outlays.

Hyperscaler Alternatives: Major cloud providers are designing in-house AI accelerators, posing a threat to Nvidia’s core customer base.

Modeling the Downside: DCF Assumptions
Seaport’s $100 target stems from a discounted cash flow analysis using a 7.5% long-term growth rate and an 11.5% discount rate, projecting muted free-cash-flow expansion once AI budgets cool in 2026.
Analyst Consensus vs. Seaport’s Bear View
While Seaport stands alone with its Sell call, the broader analyst community remains constructive. According to Financial Modeling Prep’s Price Target Summary API, the consensus 12-month price target for NVDA sits approximately 30% above current levels—underscoring the divergence between Seaport’s cautious stance and the Street’s average outlook.

Subscribe to get Latest News Updates

Latest News

You may like more
more

KBR, Inc. (NYSE:KBR) Overview: A Potential Investment Opportunity

Monthly gain of 1.20% indicates a steady upward trend...

Sanofi to Acquire Blueprint Medicines for $9.5?B, Bolstering Immunology Pipeline

French pharma leader Sanofi (NASDAQ:?SNY) announced on Monday that...

Early Use of Camizestrant Cuts Progression Risk by 56 percent in HR+/HER2– Breast Cancer

Treating women with hormone receptor–positive, HER2-negative breast cancer using...